Trials / Completed
CompletedNCT04169061
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
A Multicenter, Open-label Study to Assess the Efficacy and Safety of Acthar® Gel in Subjects With Severe Keratitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with Acthar gel * 4 weeks to wean off Acthar gel and follow-up with the doctor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acthar | Acthar gel for subcutaneous injection |
Timeline
- Start date
- 2019-11-13
- Primary completion
- 2020-11-09
- Completion
- 2020-12-07
- First posted
- 2019-11-19
- Last updated
- 2021-08-18
- Results posted
- 2021-08-18
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04169061. Inclusion in this directory is not an endorsement.